nab paclitaxel plus gemcitabine

PreclinicalSmall molecule

nab paclitaxel plus gemcitabine is one of 31 small molecule programs targeting Pancreatic Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

MS Contin

1 3

Medrol

Pfizer

Preclinical

1 4

Byetta

AstraZeneca

Preclinical

1 5

Active Comparator

Moderna

Preclinical

1 6

Chemotherapy Agents

Takeda

Preclinical

1 7

Secretin-Ferring

Ferring

Preclinical

1 8

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

2 9

Rybelsus

Pfizer

Preclinical

1 10

Gemcitabine/nab-Paclitaxel

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2/3Recruiting

Pancreatic Cancer

NCT06361888

Clinical

Trials by Indication[1]

Pancreatic Cancer4 trials

Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Completed·—··NCT04133155·103 enrolled

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Recruiting·HHutchmed·Phase 2/3·NCT06361888·502 enrolled

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Unknown status·FFudan University·Phase 3·NCT04617821·300 enrolled

Show 1 more trial

Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

Unknown status·—·Phase 2·NCT03278015·90 enrolled

Locally Advanced1 trial

Pancreatic Locally Advanced Irresectable Cancer Ablation

Unknown status·—·N/A·NCT03690323·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for nab paclitaxel plus gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nab paclitaxel plus gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nab paclitaxel plus gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFudan University

nab paclitaxel plus gemcitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Pancreatic Cancer4 trials

Locally Advanced1 trial

References

Drug Info

Quick Facts

Related News